e-ISSN: 2807-6257

Open Access Indonesian Journal of Medical Reviews

[OAIJMR]

https://hmpublisher.com/index.php/oaijmr

# Comparative Evaluation of Target-Controlled Infusion versus Syringe Pump Bolus for Remifentanil Administration on the Incidence of Apnoea and Bradycardia during General Anaesthesia Induction: A Double-Blind Pilot Randomised Controlled Trial

**Ardhana Surya Aji[1*], Bambang Novianto Putro[1], Andy Nugroho[1]**

[1]Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Universitas Sebelas Maret/Dr. Moewardi Regional General Hospital, Surakarta, Indonesia

**ARTICLE INFO**

**Keywords:**
General anaesthesia
Opioid-induced respiratory depression
Remifentanil
Syringe pump
Target-controlled infusion

***Corresponding author:**
Ardhana Surya Aji

**E-mail address:**
*ardhana.surya@student.uns.ac.id*

All authors have reviewed and approved the final version of the manuscript.

*https://doi.org/10.37275/oaijmr.v6i2.876*

**A B S T R A C T**

Remifentanil is widely utilized during general anaesthesia induction to attenuate adverse haemodynamic responses to tracheal intubation. However, its profound analgesic efficacy is inherently linked to dose-dependent adverse effects, primarily opioid-induced respiratory depression (apnoea) and bradycardia. This pilot study evaluates the safety profile of pharmacokinetically guided target-controlled infusion (TCI) compared to conventional syringe pump (SP) bolus administration. A double-blind, pilot randomised controlled trial was conducted involving 36 ASA I–II patients undergoing elective maxillofacial surgery. Patients received a standardized co-induction of propofol (2.0 mg/kg), followed by remifentanil via SP (1 µg/kg over 60 seconds) or TCI (initial effect-site concentration [Ce] of 6 ng/mL for 5 minutes, reduced to 4 ng/mL). Primary outcomes were the incidence of apnoea (>15 seconds) and bradycardia (<50 bpm). Apnoea occurred in 33.3% of the SP group versus 16.7% in the TCI group (RR 2.00; p=0.222). Mean onset of apnoea was 41.0±11.0 seconds (SP) and 31.0±3.6 seconds (TCI) (p=0.085). Bradycardia was observed in 72.2% of the SP cohort and 50.0% in the TCI cohort (RR 1.44; p=0.153). All bradycardic events were transiently managed with 0.5 mg of atropine. In conclusion, in this pilot cohort, remifentanil delivered via TCI did not achieve statistical superiority over SP bolus administration in reducing the incidence of apnoea or bradycardia. Fully powered clinical trials are required to definitively establish any pharmacokinetic safety advantages.

## 1. Introduction

The induction phase of general anaesthesia is a critical and highly vulnerable period in the perioperative journey, characterized by rapid and often profound physiological transitions.[1] Among the most significant provocations encountered during this phase is the process of direct laryngoscopy and subsequent tracheal intubation. This mechanical intervention acts as a profound nociceptive stimulus, aggressively activating the sympathetic nervous system and triggering a massive, instantaneous release of endogenous catecholamines into the systemic circulation. Clinically, this sympathetic surge manifests as severe tachycardia, marked systemic hypertension, and a dangerous escalation in myocardial oxygen demand. In vulnerable patient populations, particularly those with underlying coronary artery disease, compromised ventricular compliance, or baseline hypertension, these abrupt haemodynamic fluctuations can precipitate myocardial ischemia, perilous arrhythmias, or acute left ventricular failure. Furthermore, the autonomic

autonomic reflex triggered by airway manipulation can substantially elevate intracranial and intraocular pressures, adding further risk to neurosurgical or ophthalmic procedures.

To mitigate these profound and potentially deleterious haemodynamic fluctuations, anaesthesiologists universally incorporate potent pharmacological adjuncts into the induction sequence. The traditional reliance on deep planes of volatile anaesthetics to blunt airway reflexes has largely been superseded by the strategic co-administration of intravenous hypnotic agents and profound analgesics.[2] Prominently featured in this balanced anaesthesia approach are ultra-short-acting μ-opioid receptor agonists, with remifentanil serving as the contemporary gold standard. Remifentanil is uniquely distinguished within the broader opioid class by its exceptionally rapid onset, highly predictable pharmacokinetics, and a distinct, organ-independent metabolic pathway. Unlike legacy opioids such as fentanyl, morphine, or sufentanil, which rely heavily on hepatic biotransformation and renal excretion, remifentanil is rapidly hydrolyzed by nonspecific blood and tissue esterases. This unique degradation mechanism ensures that the drug is broken down almost immediately upon entering the systemic circulation, resulting in a remarkably brief terminal half-life. Consequently, remifentanil lacks the context-sensitive half-time prolongation that restricts the continuous infusion of other opioids. Whether infused for ten minutes or ten hours, remifentanil clears from the blood plasma and effect-site at a constant, rapid rate upon cessation. This provides a distinct clinical advantage, allowing for precise, minute-to-minute intraoperative titration of profound analgesia without the lingering threat of delayed emergence or prolonged postoperative respiratory depression.

However, the profound depth of anaesthesia and robust analgesia achieved with remifentanil is intrinsically linked to potent, dose-dependent adverse effects that severely complicate its administration during the volatile induction phase.[3] The most clinically consequential of these complications is opioid-induced respiratory depression, rapidly culminating in complete apnoea. The underlying central pathophysiology of remifentanil-induced apnoea is heavily dependent on the profound, rapid activation of high-affinity μ-opioid receptors, which are primarily encoded by the Oprm1 gene. These receptors are densely aggregated within critical brainstem respiratory networks, most notably the preBötzinger complex located in the ventrolateral medulla, which is directly responsible for generating the spontaneous inspiratory rhythm. Additionally, these receptors populate the pontine Kölliker-Fuse nucleus, a region that actively modulates the delicate transition between the inspiratory and expiratory respiratory phases. When remifentanil rapidly crosses the blood-brain barrier and binds to these receptors, it triggers an intracellular signalling cascade involving G-protein-gated inwardly rectifying potassium channels. The ensuing ionic shift deeply hyperpolarizes the postsynaptic membrane, effectively silencing the respiratory pacemaker neurons, depressing both intrinsic hypoxic and hypercapnic ventilatory drives, and inducing immediate respiratory arrest.

Concurrently, the potent activation of μ-opioid receptors elicits significant, vagally-mediated bradycardia frequently accompanied by acute hypotension. Remifentanil precipitates profound bradycardia through multiple intersecting central and peripheral mechanisms. Centrally, the drug induces a state of profound vagotonia originating from the medulla, massively increasing parasympathetic outflow to the heart. Peripherally, remifentanil exerts direct physiological suppression of the sinoatrial node pacemaker automaticity while simultaneously imposing deleterious pharmacological impacts that delay atrioventricular nodal conduction velocities. This dual depression of both the impulse generation and conduction systems renders the patient highly susceptible to precipitous drops in heart rate, requiring immediate vigilance and readiness to administer vagolytic rescue agents.[4]

The clinical consequences of failing to manage these adverse events during induction can be severe.

Apnoea, if unrecognized or improperly managed in a patient with a difficult airway, rapidly progresses to severe hypoxemia, hypercapnia, and subsequent anoxic brain injury. The period between the loss of spontaneous ventilation and the successful securing of the endotracheal tube is arguably the most critical window in any surgical procedure.[5] Similarly, unmanaged bradycardia can quickly deteriorate into critical haemodynamic instability. When the heart rate drops precipitous, cardiac output falls in tandem, compromising perfusion to vital organs. In extreme cases, opioid-induced central vagotonia can lead to asystole, requiring immediate advanced life support interventions. Therefore, optimizing the delivery of these essential but dangerous drugs is a fundamental prerequisite for patient safety.

Furthermore, the induction phase rarely relies on a single pharmacological agent. Instead, it involves a carefully choreographed sequence of drugs designed to induce unconsciousness, provide analgesia, and facilitate muscle relaxation. Propofol, a highly lipophilic substituted phenol, is the most frequently utilized induction agent worldwide. When propofol is co-administered with remifentanil, the two drugs exhibit profound pharmacological synergism.[6] This synergism is not merely additive; the presence of one agent exponentially amplifies the clinical effects of the other. While this interaction is highly desirable for rapidly achieving a deep plane of surgical anaesthesia and blunting the intubation reflex, it concurrently magnifies the risk profile. The combination drastically lowers the threshold for opioid-induced respiratory depression and exacerbates the suppression of sympathetic tone. Consequently, comparing remifentanil delivery methods requires a highly controlled environment where the synergistic influence of the hypnotic agent is rigorously standardized.

Given this incredibly narrow therapeutic index, the methodology chosen to deliver remifentanil becomes a critical determinant of physiological stability. In contemporary anaesthetic practice, remifentanil is delivered primarily via two intravenous methodologies: manual bolus infusion using a conventional syringe pump and advanced target-controlled infusion. Traditional syringe pump bolus administration is fundamentally a weight-based approach that delivers a fixed mass of drug over a fixed period. In clinical practice, a common induction dose might involve the administration of one microgram per kilogram of body weight injected precisely over sixty seconds. While simple to calculate and execute, this manual methodology carries significant pharmacokinetic flaws. A fixed-rate bolus creates a precipitous, uncontrolled spike in plasma drug concentration that frequently overshoots the desired therapeutic window. This rapid influx of the drug massively overpowers the receptor activation thresholds in the central nervous system and the cardiovascular control centres, dramatically increasing the risk of adverse physiological events. The pharmacokinetic volatility intrinsic to rapid manual bolus dosing essentially forces the anaesthesiologist to accept a brief period of physiological instability to achieve the necessary intubation conditions.[7]

Conversely, target-controlled infusion employs advanced, real-time pharmacokinetic and pharmacodynamic mathematical modelling to optimize drug delivery. The evolution of target-controlled infusion represents a significant paradigm shift in intravenous anaesthesia, moving away from subjective clinical estimates toward objective, individualized computations. Target-controlled infusion utilizes sophisticated algorithms to continuously alter the infusion rate based on calculated drug distribution, intercompartmental clearance, and elimination rates. Specifically, for remifentanil, the Minto model is globally utilized to precisely titrate infusion rates. This model incorporates multiple patient covariates, including age, weight, height, and gender, to accurately estimate the patient's specific central compartment volume and systemic clearance.[8] Because remifentanil does not distribute extensively into adipose tissue, dosing strategies based strictly on total body weight in obese patients frequently result in massive overdoses. The

Minto algorithm automatically calculates lean body mass based on the patient's biometrics, subsequently adjusting the volume of the central compartment to prevent toxic accumulation.

A defining advantage of target-controlled infusion is its ability to target the effect-site concentration rather than merely the blood plasma concentration.[9] The effect-site represents the theoretical compartment where the drug exerts its clinical action, which, for remifentanil, is the brain. Because there is an inherent temporal delay for the drug to cross the blood-brain barrier and reach equilibrium—a variable represented mathematically by the rate constant kE0—targeting the plasma concentration alone can result in a lag in clinical effect. By setting the target-controlled infusion pump to achieve and maintain a steady-state effect-site concentration, the algorithm calculates the exact initial bolus required to drive the drug across the blood-brain barrier rapidly, followed by a dynamically decreasing maintenance infusion to prevent accumulation. This mathematical precision effectively minimizes peak-trough variability, theoretically mitigating the extreme plasma concentration peaks that trigger immediate respiratory arrest and profound bradycardia.

While the general haemodynamic efficacy, rapid offset, and mathematical elegance of remifentanil target-controlled infusion are thoroughly documented in the literature, a direct, highly controlled clinical comparison of apnoea and bradycardia incidence between weight-based syringe pump boluses and mathematically modelled target-controlled infusion techniques remains a critical gap in contemporary evidence. The majority of existing pharmacokinetic research and comparative studies have largely focused on the maintenance phase of general anaesthesia or highly controlled conscious sedation environments. In these settings, the patient is already physiologically stabilized, and the drug is titrated slowly to effect. However, the induction phase is inherently volatile, characterized by the rapid, simultaneous administration of multiple profound central nervous system depressants. Evaluating how the delivery mechanics of remifentanil influence adverse events specifically during this chaotic, high-risk window is essential for refining clinical guidelines.[10] This study aims to compare the incidence of apnoea and bradycardia following remifentanil administration via syringe pump versus target-controlled infusion during general anaesthesia induction. The novelty of this study lies in its focused, head-to-head evaluation of early induction-phase adverse events using a rigorous double-blind, standardized co-induction randomised controlled design, providing essential pilot evidence to guide safer, pharmacokinetically optimized opioid administration protocols.

## 2. Methods

### Study design and setting

This double-blind, parallel-group, pilot randomised controlled trial (RCT) was conducted at the Central Surgical Installation of Dr. Moewardi Regional General Hospital, Surakarta, Indonesia. The study protocol adhered strictly to the ethical principles outlined in the Declaration of Helsinki and was granted formal ethical approval by the Health Research Ethics Committee of the Faculty of Medicine, Universitas Sebelas Maret. Written informed consent was systematically obtained from all enrolled participants prior to the day of surgery.

### Participants

The study population strictly comprised adult patients aged 17–50 years, classified under the American Society of Anesthesiologists (ASA) physical status I or II, presenting with a normal body mass index (BMI) of 18.5–24.9 kg/m$^2$. All patients were scheduled for elective maxillofacial surgery (predominantly multiple impacted teeth extraction) under general anaesthesia. Exclusion criteria were stringently applied to minimize physiological confounding variables and included: any history of respiratory diseases (asthma, chronic obstructive pulmonary disease), cardiovascular comorbidities, hepatic or renal impairment, prior beta-blocker therapy, anatomical predictors of a difficult airway,

pre-existing bradyarrhythmia, or an implanted permanent pacemaker.

**Randomisation and blinding**

Patients were allocated in a 1:1 ratio into the SP group or the TCI group utilizing a computer-generated random number table. A robust double-blind methodology was rigorously enforced. A dedicated research assistant, unblinded solely to the group allocation, prepared the remifentanil solutions and programmed the infusion devices. Because a syringe pump pushing a bolus over 60 seconds behaves visibly and audibly differently than a TCI pump running continuously, the physical delivery mechanisms were entirely concealed behind an opaque surgical drape. Concurrently, a second research assistant and the primary attending anaesthesiologist, both strictly blinded to the delivery method and shielded from the pump interfaces, continuously monitored the patient and recorded the incidence of all primary outcomes.

**Interventions and co-induction protocol**

To eliminate the profound confounding effects of variable hypnotic dosing, a standardized co-induction protocol was strictly enforced. All patients in both cohorts received an initial intravenous administration of propofol at an exact dose of 2.0 mg/kg, delivered over 30 seconds, immediately prior to the remifentanil intervention. In group SP (syringe pump), patients received remifentanil (dissolved in 0.9% NaCl at a concentration of 50 µg/mL) delivered via a standard mechanical syringe pump at a weight-based dose of 1 µg/kg, administered precisely over 60 seconds. In group TCI (target-controlled infusion), patients received remifentanil administered via a specialized TCI pump utilizing the Minto pharmacokinetic/pharmacodynamic model. To account for the blood-brain barrier equilibration delay (kE0), the pump was specifically set to target the effect-site concentration (Ce) rather than blood plasma. The dosing regimen was initiated at a target Ce of 6 ng/mL for 5 minutes, subsequently reduced to a maintenance Ce of 4 ng/mL.

**Outcome measures**

Primary and secondary outcomes were captured exclusively during the high-volatility 5-minute induction period prior to surgical incision. Apnoea was defined strictly as the complete cessation of spontaneous breathing for a continuous duration exceeding 15 seconds, clinically verified by the supervising anaesthesiologist via capnography and chest excursion. Apnoeic episodes were managed promptly with controlled mask ventilation. Bradycardia was defined as a precipitous drop in heart rate to fewer than 50 beats per minute, continuously monitored via 5-lead electrocardiography (ECG). Associated non-invasive blood pressure (NIBP) drops to a Mean Arterial Pressure (MAP) < 65 mmHg were recorded simultaneously. Bradycardia was treated with a standardized rescue dose of intravenous Atropine Sulphate (0.5 mg). Secondary outcomes included the temporal onset of apnoea (measured in seconds from the start of remifentanil infusion) and the onset of bradycardia (measured in minutes).

**Sample size and statistical analysis**

Historically, experimental designs in this setting utilized the Federer formula: $(t-1)(r-1) > 15$, which established a base requirement of 16 subjects per group. Factoring in a 10% dropout buffer, 36 participants (18 per group) were recruited. However, this study acknowledges that a formal a priori clinical power analysis for binary categorical outcomes was not conducted; thus, this cohort represents a pilot feasibility trial. Data analysis was executed using SPSS version 25. Normally distributed continuous variables (such as standardized propofol doses and age) are presented as mean ± standard deviation (SD), and non-normally distributed temporal data as median ± interquartile range (IQR). Statistical comparisons utilized the independent samples t-test, Mann-Whitney U test, or Fisher's exact test for proportional differences (apnoea and bradycardia), as statistically appropriate. Relative Risk (RR) with 95% Confidence Intervals (CI) was calculated for adverse

events. Significance was established at a strict p-value of < 0.05.

### 3. Results and Discussion

A total of 36 adult patients were randomly allocated into the syringe pump and target-controlled infusion cohorts, with eighteen subjects in each arm (Table 1). Analysis of the baseline demographic and clinical parameters confirms a high degree of homogeneity between the two treatment groups, effectively validating the randomisation process and minimizing confounding variables prior to the induction sequence. The study population was notably young, presenting with a median age of 25.5 years in the syringe pump cohort and 28.5 years in the target-controlled infusion cohort (p=0.438). This youthful demographic is directly attributable to the surgical indication; a substantial majority of the participants—66.7 percent in the manual bolus group and 100 percent in the pharmacokinetically guided group—were scheduled for the extraction of multiple impacted teeth (p=0.126). The distribution of biological sex showed a higher proportion of males in the syringe pump group, though this variance did not reach statistical significance (p=0.060).

Crucially for cardiovascular and respiratory comparisons, pre-operative physiological metrics were statistically equivalent. Baseline heart rates (82 versus 84 beats per minute, p=0.552) and mean arterial pressures (92 versus 90 millimetres of mercury, p=0.481) were highly comparable. To isolate the specific effects of the remifentanil delivery mechanisms, the co-induction hypnotic agent was strictly controlled. The mean administered propofol dose was 124.5 milligrams for the syringe pump cohort and 126.2 milligrams for the target-controlled cohort. This lack of statistical difference (p=0.654) confirms a uniform hypnotic load. Consequently, any subsequent physiological shifts—including the comparable post-induction heart rate drops to 49 and 52.44 beats per minute (p=0.205)—can be attributed strictly to the opioid administration technique rather than baseline inequalities.

**Table 1. Baseline Characteristics and Induction Parameters of Study Participants**

| CHARACTERISTIC | SP GROUP (N=18) | TCI GROUP (N=18) | P-VALUE |
|---|---|---|---|
| **Age (years), median ± IQR** | 25.5 ± 24 | 28.5 ± 15 | *0.438* |
| **Sex (Male), n (%)** | 8 (44.4%) | 2 (11.1%) | *0.060* |
| **Diagnosis (Multiple Impacted), n (%)** | 12 (66.7%) | 18 (100%) | *0.126* |
| **Propofol Co-induction Dose (mg), mean ± SD** | 124.5 ± 12.1 | 126.2 ± 10.8 | *0.654* |
| **Baseline HR (bpm), mean ± SD** | 82 ± 11 | 84 ± 10 | *0.552* |
| **Post-induction HR (bpm), mean ± SD** | 49 ± 9 | 52.44 ± 8.33 | *0.205* |
| **Baseline MAP (mmHg), mean ± SD** | 92 ± 8 | 90 ± 9 | *0.481* |

Across the entire pilot cohort, nine patients (25.0%) experienced transient, strictly defined clinical apnoea (>15 seconds) (Table 2). In the SP group, apnoea was recorded in 6 patients (33.3%), compared to exactly half that number, 3 patients (16.7%), in the TCI group. Although the relative risk was mathematically elevated twofold in the SP group (RR 2.00; 95% CI 0.52–12.14), Fisher's exact test revealed that this difference did not reach statistical significance within this sample size (p=0.222). The temporal onset of apnoea trended earlier in the TCI group (31.0 ± 3.6 seconds) versus the SP group (41.0 ± 11.0 seconds). Notably, the variance (Standard Deviation) in apnoea onset was exceptionally wide in the manual SP group (11.0s) compared to the tightly controlled TCI cohort (3.6s), though the median temporal difference remained statistically non-significant (p=0.085).

**Table 2. Comparison of Apnoea Incidence**

| GROUP | APNOEA: YES, N (%) | APNOEA: NO, N (%) | RELATIVE RISK (95% CI) | P-VALUE |
|---|---|---|---|---|
| **SP (n=18)** | 6 (33.3%) | 12 (66.7%) | **2.00 (0.52–12.14)** | *0.222* |
| **TCI (n=18)** | 3 (16.7%) | 15 (83.3%) | — | — |

Bradycardia emerged as a highly prominent adverse cardiovascular event during induction, occurring in 22 patients (61.1%) overall (Table 3). The syringe pump (SP) group exhibited a higher absolute incidence, with 13 patients (72.2%) developing significant bradycardia (<50 bpm) compared to 9 patients (50.0%) in the pharmacokinetically modelled TCI group. This yielded a relative risk of 1.44 (95% CI 0.84–2.49); however, parallel to the apnoea outcomes, the difference remained statistically non-significant (p=0.153). The median onset time to bradycardia was highly comparable between the methodologies: 3 ± 1 minutes in the SP group and 2 ± 2 minutes in the TCI group (p=0.431). Crucially, all bradycardic episodes observed in this trial were transient. Every event was accompanied by corresponding hypotension (MAP < 65 mmHg) and was managed safely and effectively with a single standard pharmacological intervention of intravenous Atropine Sulphate (0.5 mg), completely negating the need for advanced resuscitation or transcutaneous pacing.

**Table 3. Comparison of Bradycardia Incidence**

| GROUP | BRADYCARDIA: YES, N (%) | BRADYCARDIA: NO, N (%) | RELATIVE RISK (95% CI) | P-VALUE |
|---|---|---|---|---|
| **SP (n=18)** | 13 (72.2%) | 5 (27.8%) | **1.44 (0.84–2.49)** | *0.153* |
| **TCI (n=18)** | 9 (50.0%) | 9 (50.0%) | — | — |

This double-blind pilot randomised controlled trial rigorously evaluated the comparative safety and physiological impacts of two ubiquitous remifentanil delivery modalities—syringe pump bolus versus target-controlled infusion—specifically during the highly volatile induction phase of general anaesthesia. The induction sequence represents a period of extreme physiological vulnerability, characterized by rapid shifts in autonomic tone and the profound suppression of protective airway reflexes. Laryngoscopy and tracheal intubation trigger a massive afferent sensory surge via the glossopharyngeal and vagus nerves, which is integrated within the brainstem and rapidly produces a robust efferent sympathetic outflow. This translates clinically to severe tachycardia, marked hypertension, and potentially catastrophic increases in myocardial oxygen demand. While no definitive statistical superiority was established for either technique regarding the absolute incidence of apnoea or bradycardia, exploring the underlying molecular pathophysiology highlights why rapid opioid delivery mechanics drastically influence central nervous system and cardiovascular networks. The decision between manual bolus delivery and pharmacokinetically modelled infusion is not merely a matter of clinical preference or convenience; it fundamentally alters the temporal profile of drug distribution within the central compartment. This temporal divergence dictates the intensity, onset, and duration of adverse events, necessitating a deep understanding of how remifentanil interacts with specific neuro-cardiovascular networks to optimize patient safety during the high-stakes intubation window.[11]

The overall apnoea incidence of 25.0 percent observed in our controlled cohort accurately mirrors broader epidemiological data concerning opioid-induced respiratory depression during co-induction with propofol. The underlying pathophysiology of remifentanil-induced apnoea is heavily dependent on the profound, rapid activation of μ-opioid receptors, which are primarily encoded by the Oprm1 gene.[12] These high-affinity receptors are densely aggregated within two critical brainstem respiratory networks: the preBötzinger complex located in the ventrolateral medulla, which is directly responsible for generating the spontaneous inspiratory rhythm, and the pontine Kölliker-Fuse nucleus, which actively modulates the delicate transition between inspiratory and expiratory respiratory phases.[13]

When a highly lipophilic opioid like remifentanil rapidly crosses the blood-brain barrier and binds to these μ-opioid receptors, it triggers a catastrophic G-protein-coupled intracellular signaling cascade. This cascade involves the direct inhibition of the enzyme adenylate cyclase, leading to a marked reduction in the synthesis of intracellular cyclic adenosine monophosphate. Concurrently, this pathway dramatically activates G-protein-gated inwardly rectifying potassium channels. The sudden, uninhibited efflux of potassium out of the intracellular space causes a massive ionic shift, deeply hyperpolarizing the postsynaptic membrane. This hyperpolarization effectively and instantly silences the respiratory pacemaker neurons within the preBötzinger complex.[14] Consequently, both the central chemoreceptor sensitivity to carbon dioxide and the peripheral chemoreceptor sensitivity to hypoxia are heavily depressed, ultimately inducing complete, sudden-onset apnoea. The rapidity of this central nervous system penetration makes remifentanil uniquely potent in abolishing spontaneous ventilation compared to legacy opioids.

The mechanistic disparity in apnoea rates—33.3 percent via manual syringe pump versus 16.7 percent via mathematically guided target-controlled infusion—likely stems from the pharmacokinetic volatility intrinsic to rapid manual bolus dosing. The 60-second manual syringe pump bolus creates a precipitous, uncontrolled, and transient spike in plasma drug concentration. This massive influx of molecules simultaneously overpowers the μ-opioid receptor activation threshold in the preBötzinger complex, leaving the respiratory control centers entirely overwhelmed by the sheer concentration gradient.[15]




**Figure 1. Central Pathophysiology of Opioid-Induced Respiratory Depression** This sequence illustrates the neuro-anatomical cascade triggered by rapid opioid administration. Displaying the exact mechanisms by which remifentanil interrupts the automaticity of brainstem respiratory networks from initial delivery to clinical apnoea.

Conversely, advanced target-controlled infusion algorithms like the Minto model elegantly govern the real-time infusion rate by continuously calculating drug distribution across theoretical physiological compartments, accounting for intercompartmental clearance, and accurately predicting elimination. By targeting an effect-site concentration of 6 nanograms per milliliter, the target-controlled infusion pump precisely modulates the drug delivery to mitigate the extreme plasma concentration peaks that trigger immediate respiratory arrest. This calculated equilibrium prevents the catastrophic receptor saturation seen with manual boluses, resulting in the tighter standard deviation (3.6 seconds versus 11.0 seconds) observed in apnoea onset times.[16] The mathematical governance of the infusion ensures a smoother, more predictable transit of the drug across the blood-brain barrier, theoretically preserving a narrow margin of intrinsic respiratory drive slightly longer than a crude manual push.

Bradycardia manifested in 61.1 percent of our total cohort, emphatically emphasizing remifentanil's potent and uniquely aggressive cardiovascular profile. Pathophysiologically, remifentanil precipitates profound bradycardia through three intersecting central and peripheral mechanisms. First and foremost is the rapid induction of profound central vagotonia originating from the medulla oblongata. Remifentanil intensely stimulates the vagal motor nuclei, specifically the nucleus ambiguus and the dorsal motor nucleus of the vagus, triggering a massive parasympathetic efferent surge down the vagus nerve. Second, the drug exerts a direct physiological suppression of sinoatrial node pacemaker automaticity. It achieves this by decreasing the slow inward calcium current and increasing the outward potassium current, thereby prolonging the time required for the pacemaker cells to reach the threshold potential. Third, it induces deleterious pharmacological impacts that delay atrioventricular nodal conduction velocities, prolonging the PR interval on the electrocardiogram and occasionally inducing varying degrees of transient heart block.[17]

Our recorded bradycardia incidence was notably higher than the rates documented in strictly observational sedation cohorts or geriatric maintenance studies. This is logically attributable to the exceptionally young median age (25.5 to 28.5 years) and naturally elevated, robust baseline vagal tone of our specific maxillofacial surgery demographic.[18] In young, healthy individuals, the parasympathetic nervous system exerts a dominant resting influence over the heart. The rapid administration of an ultra-short-acting opioid like remifentanil unmasks and heavily amplifies this pre-existing vagal dominance, resulting in the precipitous

heart rate drops to fewer than 50 beats per minute and corresponding hypotension observed in this trial. The cardiovascular system of a younger patient reacts with a much more profound reflex arc compared to older populations, who may possess attenuated autonomic responses due to age-related vascular stiffness or pre-existing beta-blocker therapy. Notably, the successful reversal of these events with a purely antimuscarinic agent, Atropine 0.5 milligrams, confirms that the mechanism is primarily vagally mediated rather than a manifestation of direct myocardial depression or structural ischemia. By competitively binding to muscarinic receptors on the sinoatrial and atrioventricular nodes, Atropine effectively blocks the excessive acetylcholine released by the remifentanil-induced central vagotonia, swiftly restoring both chronotropic and dromotropic cardiac function.[19]

The interpretation of this pilot data must be contextualized within three primary structural and methodological limitations. First and foremost, the study was not formally powered a priori using clinical proportion calculations to detect statistically significant differences in binary adverse events. Relying on the agricultural Federer formula restricts this research entirely to the status of a feasibility pilot, precluding definitive clinical conclusions regarding statistical superiority. The restricted sample size vastly increases the probability of a Type II statistical error, wherein a genuine, clinically meaningful difference between the two delivery methods might actually exist but remains undetected due to insufficient statistical power. Second, there is an unavoidable pharmacokinetic divergence in absolute dosing mechanics that complicates direct comparative analysis. Comparing a rapid, fixed weight-based bolus of 1 microgram per kilogram to a continuous concentration-targeted model of 6 nanograms per milliliter complicates a pure parallel comparison. In the earliest 60 seconds of induction, the syringe pump group mathematically received a much denser cumulative microgram dose compared to the gradual, algorithm-driven ramping of the target-controlled infusion. This creates an inherently unequal physiological challenge at the immediate start of the surgical procedure, skewing the very early adverse event profile. Third, while the co-induction hypnotic dose of propofol was strictly standardized to eliminate variable hypnotic synergism, individual biological variations in hepatic blood flow, cardiac output, and exact central compartment volume (V1) could subtly alter the pharmacokinetics of both drugs, creating invisible, patient-specific disparities. The Minto model attempts to account for these covariates, but a manual weight-based syringe pump dose cannot. Future large-scale, multi-center trials are absolutely imperative to resolve these limitations. Subsequent studies must utilize strict clinical power calculations and explore carefully titrated, equimolar dosing regimens to truly isolate the variable of delivery speed and mechanics from total dose administration.[20]

**4. Conclusion**

In this rigorously double-blinded pilot randomised controlled trial incorporating standardized propofol co-induction, the administration of remifentanil via target-controlled infusion utilizing the Minto model did not achieve statistical superiority over traditional syringe pump bolus dosing in reducing the overall incidence of apnoea and bradycardia during general anaesthesia induction. While the theoretical, mathematical advantages of pharmacokinetic modeling are highly robust, translating that mathematical elegance into definitively superior, statistically significant clinical safety outcomes remains challenging within the highly volatile and chaotic context of rapid sequence induction. Both delivery techniques present substantial, inherent risks of profound central respiratory depression and vagally mediated cardiovascular collapse. The sophisticated nature of a target-controlled infusion pump does not absolve the clinician from the fundamental tenets of vigilant airway and haemodynamic management. The findings strictly underscore the critical necessity for rigorous, uninterrupted respiratory monitoring via continuous waveform capnography, alongside continuous cardiovascular surveillance utilizing

continuous electrocardiography and frequent non-invasive blood pressure tracking. Furthermore, the immediate, bedside availability of vagolytic rescue medications, such as Atropine or Glycopyrrolate, is an absolute, non-negotiable prerequisite during remifentanil induction, irrespective of whether the drug is delivered via a crude manual push or an advanced algorithmic system. Optimizing patient safety and minimizing morbidity during this high-stakes period relies less heavily on the specific infusion technology utilized, and far more heavily on the rapid clinical recognition and immediate pharmacological mitigation of entirely predictable opioid-induced physiological derangements.

**5. References**


1. Scarlata S, Costa F, Pascarella G, et al. Remifentanil target-controlled infusion for conscious sedation in endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): a case series. Clin Drug Investig. 2020; 40(10): 985–8.
2. Caron M, Parrot A, Elabbadi A, et al. Pain and dyspnea control during awake fiberoptic bronchoscopy in critically ill patients: safety and efficacy of remifentanil target-controlled infusion. Ann Intensive Care. 2021; 11(1): 48.
3. Zhou Y, Wu W, Zhu Y, et al. Inhibition of stress and spontaneous respiration: Efficacy and safety of monitored anesthesia care by target-controlled infusion remifentanil in combination with dexmedetomidine in fibreoptic bronchoscopy for patients with severe tracheal stenosis. Front Med (Lausanne). 2022; 9: 972066.
4. Motamed C, Servin F, Billard V. Adding low-dose propofol to limit anxiety during target-controlled infusion of remifentanil for gastrointestinal endoscopy: Respiratory issues and safety recommendations. Medicina (Kaunas). 2022; 58(9): 1285.
5. Kim H-J, Cho A-R, Moon D, et al. Inadvertent free flow of remifentanil caused by a damaged syringe installed in syringe pump. Korean J Anesthesiol. 2020; 74(1): 79–81.
6. Van Hese L, Theys T, Absalom AR, et al. Comparison of predicted and real propofol and remifentanil concentrations in plasma and brain tissue during target-controlled infusion: a prospective observational study. Anaesthesia. 2020; 75(12): 1626–34.
7. Zhao P, Cui Y, Sun L, et al. Inhalation of low-dose desflurane prevents the hemodynamic instability caused by target-controlled infusion of remifentanil and propofol during laparoscopic gynecological surgery: a randomized controlled trial. Exp Ther Med. 2021; 21(1): 54.
8. Kim TK. Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil. Korean J Anesthesiol. 2021; 74(6): 478–87.
9. Potočnik I, Andjelkovič-Juvan L, Hostnik A, et al. Remifentanil target-controlled infusion with intranasal dexmedetomidine for vitreoretinal procedures: a randomized controlled trial. Croat Med J. 2021; 62(3): 233–40.
10. Scherrer V, Lamoureux F, Chaventre C, et al. Reliability of the Minto model for target-controlled infusion of remifentanil during cardiac surgery with cardiopulmonary bypass. Br J Anaesth. 2022; 129(2): 163–71.
11. Lee S, You AH, Kim M, et al. Postoperative nausea and vomiting according to target-controlled or manual remifentanil infusion in gynecological patients undergoing pelviscopic surgery: a randomized controlled trial. J Pers Med. 2023; 13(2): 176.
12. Lai H-C, Lai M-F, Huang Y-H, et al. Comparison of single target-controlled infusion pump-delivered mixed propofol and remifentanil with two target-controlled infusion pumps-delivered propofol and remifentanil in patients undergoing breast

cancer surgery-A prospective study. Int J Environ Res Public Health. 2023; 20(3): 2094.
13. Duan C, Wang B, Wang G, et al. Clinical effect of target-controlled infusion of sufentanil and remifentanil for internal thoracoscopy. Cmf. 2023;
14. Scarlata S, Scaduto V, Paglione L, et al. Remifentanil target-controlled infusion versus standard of care for conscious sedation during ultrasound-guided transbronchial needle aspiration and biopsy: a randomized, prospective, control study. J Bronchology Interv Pulmonol. 2024; 31(4).
15. Munafo' C, Loperfido A, Mammarella F, et al. Safety and efficacy of remifentanil target-controlled infusion for conscious sedation in a pregnant woman: a case report. J Med Case Rep. 2024; 18(1): 143.
16. Jun B, Yoo YC, Bai SJ, et al. Target-controlled infusion with PSI- and ANI-guided sufentanil versus remifentanil in remimazolam-based total intravenous anesthesia for postoperative analgesia and recovery after laparoscopic subtotal gastrectomy: a randomized controlled study. J Clin Med. 2025; 14(24): 8921.
17. Breazu CM, Maniu AA, Marchis IF, et al. Dexmedetomidine continuous infusion vs. Remifentanil target-controlled infusion for conscious sedation in otosclerosis surgery-A prospective, single-center, randomized controlled trial. J Clin Med. 2025; 14(9): 2869.
18. Xu Z, Zhang J, Chen L, et al. Impact of different doses of remifentanil on postoperative pain and hyperalgesia: a prospective randomized controlled study and genotypic analysis. J Clin Anesth. 2026; 111(112198): 112198.
19. Möllhoff T, Herregods L, Moerman A, et al. Comparative efficacy and safety of remifentanil and fentanyl in "fast track" coronary artery bypass graft surgery: a randomized, double-blind study. Br J Anaesth. 2001; 87(5): 718–26.
20. Kim TK, Obara S, Egan TD, et al. Disposition of remifentanil in obesity: a new pharmacokinetic model incorporating the influence of body mass. Anesthesiology. 2017; 126(6): 1019–32.